A Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Intermediate-1, Myelodysplastic Syndrome Patients Based on the International Prognostic Scoring System
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Oct 2019
Price : $35 *
At a glance
- Drugs Rigosertib (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- Sponsors Onconova Therapeutics
- 16 Oct 2019 Planned End Date changed from 1 Feb 2019 to 1 Jun 2020.
- 16 Oct 2019 Planned primary completion date changed from 1 Sep 2018 to 1 Jun 2020.
- 20 Jul 2018 Planned End Date changed from 1 Nov 2018 to 1 Feb 2019.